All In Biotech

Drug Trial Radar · NCT05638802

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Jun 7, 2023

Primary completion

Apr 1, 2025

Study completion Apr 1, 2025

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Dec 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • DS-7011aDrug

    20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57

  • PlaceboDrug

    Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus ErythematosusTime frame: Post first dose up to Week 24

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group LLC

    Anniston, Alabama

  • Arkansas Research Trials

    North Little Rock, Arkansas

  • Office of Tory P. Sullivan, M.D. - North Miami Beach

    North Miami Beach, Florida

  • West Broward Rheumatology Associates

    Tamarac, Florida

  • The University of Kansas Medical Center

    Kansas City, Kansas

  • Oakland Hills Dermatology

    Auburn Hills, Michigan

  • Revival Research Institute, LLC

    Troy, Michigan

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • Joint & Muscle Research Institute

    Charlotte, North Carolina

  • Trinity Health Center Medical Arts

    Minot, North Dakota

  • Precision Comprehensive Clinical Research Solutions

    Colleyville, Texas

  • Metroplex Clinical Research Center, LLC

    Dallas, Texas

  • Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch

    Shanghai, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Hospital of the University of Occupational and Environmental Health

    Kitakyushu-shi, Japan

  • Japan Community Health Care Organization Chukyo Hospital

    Nagoya, Japan

  • Tohoku University Hospital

    Sendai, Japan

  • Jcho Tokyo Yamate Medical Center

    Shinjuku-ku, Japan

  • Yokohama City University Medical Center

    Yokohama, Japan

  • Phi University Clinic of Rheumatology Skopje

    Skopje, North Macedonia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.